Catalyst

Slingshot members are tracking this event:

Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
LLY Community voting in process

Additional Information

Additional Relevant Details US FDA has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Taltz should not be used in patients with a previous hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. Taltz is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.
http://lilly.mediaro...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Moderate-to-severe Plaque Psoriasis, Ixekizumab, Talz